{"Title": "A Polycomb-mir200 loop regulates clinical outcome in bladder cancer", "Year": 2015, "Source": "Oncotarget", "Volume": "6", "Issue": 39, "Art.No": null, "PageStart": 42258, "PageEnd": 42275, "CitedBy": 30, "DOI": "10.18632/oncotarget.5546", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84951768968&origin=inward", "Abstract": "Bladder cancer (BC) is a highly prevalent disease, ranking fifth in the most common cancers worldwide. Various miRNAs have recently emerged as potential prognostic biomarkers in cancer. The miR-200 family, which repressed the epithelialto- mesenchymal transition (EMT), is repressed in multiple advanced cancers. However, its expression and function in BC is still poorly understood. Here we show that miR-200 family displays increased expression, probably due to the activation of specific oncogenic signaling pathways, and reduced promoter methylation, in BC compared to normal bladder samples. Furthermore, we show that the expression of these miRNAs is decreased in high grade and stage tumors, and the down-regulation is associated with patient's poor clinical outcome. Our data indicate that the miR-200 family plays distinct roles in Non-Muscle (NMIBC) and Muscle-Invasive BC (MIBC). In MIBC, miR-200 expression post transcriptionally regulates EMT-promoting transcription factors ZEB1 and ZEB2, whereas suppresses BMI1 expression in NMIBC. Interestingly, we show that increased EZH2 and/or BMI1 expression repress the expression of miR-200 family members. Collectively, these findings support a model of BC progression through a coordinated action between the Polycomb Repression Complex (PRC) members repressing the miR-200 expression, which ultimately favors invasive BC development. Since pharmacological inhibition of EZH2 in BC cell lines lead to increased miR-200 expression, our findings may support new therapeutic strategies for BC clinical management.", "AuthorKeywords": ["Bladder cancer", "Epigenetics", "MiRNA", "Polycomb", "Recurrence"], "IndexKeywords": ["Aged", "Aged, 80 and over", "Blotting, Western", "Cell Line, Tumor", "DNA Methylation", "Enhancer of Zeste Homolog 2 Protein", "Epithelial-Mesenchymal Transition", "Female", "Gene Expression Profiling", "Gene Expression Regulation, Neoplastic", "Homeodomain Proteins", "Humans", "Immunohistochemistry", "Kaplan-Meier Estimate", "Male", "MicroRNAs", "Middle Aged", "Polycomb Repressive Complex 1", "Polycomb Repressive Complex 2", "Polycomb-Group Proteins", "Prognosis", "Repressor Proteins", "Reverse Transcriptase Polymerase Chain Reaction", "Signal Transduction", "Transcription Factors", "Urinary Bladder Neoplasms", "Zinc Finger E-box-Binding Homeobox 1"], "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 1, "EID": "2-s2.0-84951768968", "SubjectAreas": [["Oncology", "MEDI", "2730"]], "AuthorData": {"8535731400": {"Name": "Mart\u00ednez-Fern\u00e1ndez M.", "AuthorID": "8535731400", "AffiliationID": "60004024", "AffiliationName": "Universitary Hospital 12 de Octubre"}, "57206503433": {"Name": "Due\u00f1as M.", "AuthorID": "57206503433", "AffiliationID": "60004024", "AffiliationName": "Universitary Hospital 12 de Octubre"}, "6603538785": {"Name": "Segovia C.", "AuthorID": "6603538785", "AffiliationID": "60004024", "AffiliationName": "Universitary Hospital 12 de Octubre"}, "6602471179": {"Name": "Garc\u00eda-Escudero R.", "AuthorID": "6602471179", "AffiliationID": "60004024", "AffiliationName": "Universitary Hospital 12 de Octubre"}, "56890583500": {"Name": "Rubio C.", "AuthorID": "56890583500", "AffiliationID": "60004024", "AffiliationName": "Universitary Hospital 12 de Octubre"}, "56891736700": {"Name": "L\u00f3pez-Calder\u00f3n F.", "AuthorID": "56891736700", "AffiliationID": "60004024", "AffiliationName": "Universitary Hospital 12 de Octubre"}, "57214528160": {"Name": "D\u00edaz-Garc\u00eda C.", "AuthorID": "57214528160", "AffiliationID": "60005233", "AffiliationName": "Molecular Oncology Unit, CIEMAT (ed70A)"}, "6701734556": {"Name": "Paramio J.", "AuthorID": "6701734556", "AffiliationID": "60004024", "AffiliationName": "Universitary Hospital 12 de Octubre"}, "15748766900": {"Name": "Villacampa F.", "AuthorID": "15748766900", "AffiliationID": "60004024", "AffiliationName": "Uro-oncology Section, Universitary Hospital 12 de Octubre"}, "55920733400": {"Name": "Duarte J.", "AuthorID": "55920733400", "AffiliationID": "60004024", "AffiliationName": "Uro-oncology Section, Universitary Hospital 12 de Octubre"}, "57052737100": {"Name": "G\u00f3mez-Rodriguez M.", "AuthorID": "57052737100", "AffiliationID": "60004024", "AffiliationName": "Uro-oncology Section, Universitary Hospital 12 de Octubre"}, "55901642500": {"Name": "Castellano D.", "AuthorID": "55901642500", "AffiliationID": "60004024", "AffiliationName": "Uro-oncology Section, Universitary Hospital 12 de Octubre"}, "7004087843": {"Name": "de la Rosa F.", "AuthorID": "7004087843", "AffiliationID": "60004024", "AffiliationName": "Uro-oncology Section, Universitary Hospital 12 de Octubre"}, "6506954566": {"Name": "Feber A.", "AuthorID": "6506954566", "AffiliationID": "60109234, 60022148", "AffiliationName": "Medical Genomics, UCL Cancer Institute, University College London"}, "57193033325": {"Name": "Beck S.", "AuthorID": "57193033325", "AffiliationID": "60109234, 60022148", "AffiliationName": "Medical Genomics, UCL Cancer Institute, University College London"}, "7005762332": {"Name": "Rodriguez-Peralto J.", "AuthorID": "7005762332", "AffiliationID": "60004024", "AffiliationName": "Anatomic Pathology Service, Universitary Hospital 12 de Octubre"}}}